{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T05:17:26Z","timestamp":1783142246808,"version":"3.54.6"},"reference-count":33,"publisher":"Japan Atherosclerosis Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,7,1]]},"DOI":"10.5551\/jat.66062","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T22:09:51Z","timestamp":1774562991000},"page":"922-936","source":"Crossref","is-referenced-by-count":0,"title":["Impact of High-Intensity Statins and Low-Density Lipoprotein Cholesterol on the Outcomes of Coronary Intervention for Chronic Coronary Syndrome in Japan"],"prefix":"10.5551","volume":"33","author":[{"given":"Yohei","family":"Yamauchi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kanzaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Shishikura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kusumoto","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Sakane","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Fujisaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahito","family":"Michikura","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Osaka Medical and Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Maron DJ, Hochman JS, Reynolds HR, Bangalore S, O\u2019Brien SM, Boden WE, Chaitman BR, Senior R, Lopez-Sendon J, Alexander KP, Lopes RD, Shaw LJ, Berger JS, Newman JD, Sidhu MS, Goodman SG, Ruzyllo W, Gosselin G, Maggioni AP, White HD, Bhargava B, Min JK, Mancini GBJ, Berman DS, Picard MH, Kwong RY, Ali ZA, Mark DB, Spertus JA, Krishnan MN, Elghamaz A, Moorthy N, Hueb WA, Demkow M, Mavromatis K, Bockeria O, Peteiro J, Miller TD, Szwed H, Doerr R, Keltai M, Selvanayagam JB, Steg PG, Held C, Kohsaka S, Mavromichalis S, Kirby R, Jeffries NO, Harrell FE Jr, Rockhold FW, Broderick S, Ferguson TB Jr, Williams DO, Harrington RA, Stone GW, and Rosenberg Y: Initial invasive or conservative strategy for stable coronary disease. N Engl J Med, 2020; 382: 1395-1407","DOI":"10.1056\/NEJMoa1915922"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Mesnier J, Ducrocq G, Danchin N, Ferrari R, Ford I, Fox KM, Greenlaw N, Tendera M, Widimsky P, and Steg PG: International observational analysis of evolution and outcomes of chronic stable angina: the multinational CLARIFY study. Circulation, 2021; 144: 512-523","DOI":"10.1161\/CIRCULATIONAHA.121.054567"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, and Califf RM: Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, and ODYSSEY OUTCOMES Committees and Investigators: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Bulbulia R, Bowman L, Wallendszus K, Parish S, Armitage J, Collins R, and Peto R: Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet, 2011; 378: 2013-2020","DOI":"10.1016\/S0140-6736(11)61125-2"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR, and FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R, and Cholesterol Treatment Trialists\u2019 (CTT) Collaboration: Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mach F, Koskinas KC, Roeters van Lennep JE, Tokgozoglu L, Nordestgaard BG, Catapano AL, Chapman MJ, and ESC\/EAS Scientific Document Group: 2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias. Atherosclerosis, 2025; 389: 120479","DOI":"10.1016\/j.atherosclerosis.2025.120479"},{"key":"9","unstructured":"9) Rints C, Andreotti F, Koskinas KC, Aboyans V, Agewall S, Badimon L, Bonaca MP, Borger MA, Brotons C, Bueno H, Catapano AL, Cosentino F, Corrada E, de Caterina R, De Carlo M, Delgado V, Drexel H, Edvardsen T, Faggiano P, Gencer B, Halvorsen S, Iung B, Jennings C, Jukema JW, Lettino M, Michalis L, Najafov R, Neumann FJ, Neskovic AN, Ouwens DM, Piepoli MF, Pinto FJ, Price S, Roffi M, Rosano G, Ruschitzka F, Schiele F, Shlyakhto E, Siontis GCM, Tendera M, Tokgozoglu L, Torbicki A, Touyz RM, Tsioufis K, van der Meer P, Vavlukis M, Vilahur G, Windecker S, Zamorano JL, and Zelveian P: 2024 ESC guidelines for the management of chronic coronary syndromes. Eur Heart J, 2024; 45: 3415-3537"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, and Skene AM: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 350: 1495-1504","DOI":"10.1056\/NEJMoa040583"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK, and Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435","DOI":"10.1056\/NEJMoa050461"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, and Yeboah J: 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol, 2019; 73: e285-e350","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Liao JK: Safety and efficacy of statins in Asians. Am J Cardiol, 2007; 99: 410-414","DOI":"10.1016\/j.amjcard.2006.08.051"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Lin JL, Chen PS, Lin HW, Chang CH, Chang WL, and Hsiao FY: Real-world analyses of the safety outcome among a general population treated with statins: an Asian population-based study. J Atheroscler Thromb, 2021; 29: 1213-1222","DOI":"10.5551\/jat.63076"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, Umemoto S, Egusa G, Ohmura H, Okamura T, Kihara S, Koba S, Saito I, Shoji T, Daida H, Tsukamoto K, Deguchi J, Dohi S, Dobashi K, Hamaguchi H, Hara M, Hiro T, Matsuzaki M, Miyamoto Y, and Yamashita S: Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. J Atheroscler Thromb, 2018; 25: 846-984","DOI":"10.5551\/jat.GL2017"},{"key":"16","unstructured":"16) Okamura T, Tsukamoto K, Arai H, Hata J, Hattori Y, Ishibashi S, Ishigaki Y, Kihara S, Kinoshita M, Koba S, Kotani K, Maruyama C, Matsuzaki M, Miyamoto Y, Morita H, Ouchi Y, Saito I, Shoji T, Yokote K, Yoshida H, and Yamashita S: Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022. J Atheroscler Thromb, 2024; 31: 641-853"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Friedewald WT, Levy RI, and Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD, and the Executive Group on behalf of the Joint European Society of Cardiology (ESC)\/American College of Cardiology (ACC)\/American Heart Association (AHA)\/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction: Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol, 2018; 72: 2231-2264","DOI":"10.1016\/j.jacc.2018.08.1038"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV, and American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, and Council on Nutrition, Physical Activity and Metabolism: An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke, 2013; 44: 2064-2089","DOI":"10.1161\/STR.0b013e318296aeca"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Gabriel Steg P, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, and Serruys PW: Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 2007; 115: 2344-2351","DOI":"10.1161\/CIRCULATIONAHA.106.685313"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Iso H: Changes in coronary heart disease risk among Japanese. Circulation, 2008; 118: 2725-2729","DOI":"10.1161\/CIRCULATIONAHA.107.750117"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kita T: Coronary heart disease risk in Japan \u2013 an East\/West divide? Eur Heart J Suppl, 2004; 6: A8-A11","DOI":"10.1016\/j.ehjsup.2004.01.003"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Matoba T, Katsuki S, Nakano Y, Nakagawa K, Ozaki Y, Yamaguchi J, and Ueda Y: Efficacy and safety of high-intensity statins in Japanese patients after percutaneous coronary intervention: insights from the clinical deep data accumulation system (CLIDAS). Circ J, 2025; 89: 1204-1215","DOI":"10.1253\/circj.CJ-25-0066"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Fujioka S, Shishikura D, Kusumoto H, Tsuda K, Sakane K, Yamauchi Y, and Kanzaki Y: Clinical impact of \u2265 50% reduction of low-density lipoprotein cholesterol following lipid-lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome. J Clin Lipidol, 2025; 19: 247-255","DOI":"10.1016\/j.jacl.2024.10.010"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Daida H, Hirayama A, Hokimoto S, Kitagawa K, Miyauchi K, Nakagawa Y, Nohara R, Ogawa H, Ohashi Y, Otsuji Y, Sakuma I, Shinke T, Takase B, Takeda Y, Yamashita T, Yoshida M, and REAL-CAD Investigators: High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD): a randomized superiority trial. Circulation, 2018; 137: 1997-2009","DOI":"10.1161\/CIRCULATIONAHA.117.032615"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Oesterle A, Laufs U, and Liao JK: Pleiotropic effects of statins on the cardiovascular system. Circ Res, 2017; 120: 229-243","DOI":"10.1161\/CIRCRESAHA.116.308537"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Liao JK, and Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol, 2005; 45: 89-118","DOI":"10.1146\/annurev.pharmtox.45.120403.095748"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Davignon J: Beneficial cardiovascular pleiotropic effects of statins. Circulation, 2004; 109: III39-III43","DOI":"10.1161\/01.CIR.0000131517.20177.5a"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN, and REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291: 1071-1080","DOI":"10.1001\/jama.291.9.1071"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, and Glynn RJ: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 2008; 359: 2195-2207","DOI":"10.1056\/NEJMoa0807646"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Egede R, Jensen LO, Hansen HS, Junker A, Kristensen SD, and Terkelsen CJ: Effect of intensive lipid-lowering treatment compared to moderate lipid-lowering treatment with rosuvastatin on endothelial function in high-risk patients. Int J Cardiol, 2012; 158: 376-379","DOI":"10.1016\/j.ijcard.2011.01.071"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kim J, Park KT, Jang MJ, Choi JH, Park TK, Yang JH, Song YB, Hahn JY, Choi SH, Gwon HC, and Lee SH: High-intensity versus non-high-intensity statins in patients achieving low-density lipoprotein cholesterol goal after percutaneous coronary intervention. J Am Heart Assoc, 2018; 7: e009517","DOI":"10.1161\/JAHA.118.009517"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ng AKY, Ng PY, Ip A, Chan SC, Chan NY, Lee MMY, and Wong CKW: High-intensity statin versus low-density lipoprotein cholesterol target for patients undergoing percutaneous coronary intervention: insights from a territory-wide cohort study in Hong Kong. Front Cardiovasc Med, 2021; 8: 760926","DOI":"10.3389\/fcvm.2021.760926"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/7\/33_66062\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:44:52Z","timestamp":1783140292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/7\/33_66062\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66062","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"66062"}}